CompletedNot Applicable

Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia

China60 participantsStarted 2024-06-01

Plain-language summary

To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with mycoplasma pneumoniae pneumonia, in comparison with placebo.

Who can participate

Age range6 Months – 12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. diagnosis of MPP based on typical clinical manifestations (e.g., fever, cough, abnormal pulmonary auscultation), radiographic evidence of pneumonia on chest imaging, and laboratory findings in accordance with current pediatric community-acquired pneumonia guidelines;
✓. MP infection was confirmed in nasopharyngeal secretions and serum samples using PCR and ELISA;
✓. age between 6 months and 12 years;
✓. disease duration less than 2 weeks;
✓. written informed consent provided by the guardians.

Exclusion criteria

✕. Previous history of wheezing;
✕. Cardiovascular disease and congenital tracheal dysplasia;
✕. pneumonia induced by other causes;
✕. Dysplasia of bronchial and pulmonary tracts;
✕. premature infants;
✕. Combined with immunosuppressive diseases;
✕. Presence of mental illness.

What they're measuring

Mycoplasma pneumoniae load

Timeframe: 7天

Trial details

NCT IDNCT06348095

SponsorWecare Probiotics Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-03-20

View on ClinicalTrials.gov More Mycoplasma Pneumoniae Pneumonia trials